BTI: The Dividend Stock That Smokes a Good Adjusted Number, But Coughs on the Reported One

# BTI: The Dividend Stock That Smokes a Good Adjusted Number, But Coughs on the Reported One

Let's get one thing straight: British American Tobacco is not a growth stock, it's a yield machine wearing a growth story's clothes. And on July 30, when the company put out its first-half 2026 results, that costume fit reasonably well — right up until you flipped to the reported numbers and found the tailoring falling apart at the seams.

The headline that made the bulls happy

BAT's H1 print, delivered by CEO Tadeu Marroco and interim CFO Javed Iqbal, came in "in line with expectations" — corporate-speak for "nothing blew up." On a constant-currency, adjusted basis: group revenue up 2.9%, adjusted gross profit up 3.8%, adjusted profit from operations up 3.5%, and adjusted diluted EPS up a genuinely respectable 7.9%. The star of the show was New Category revenue — modern oral, read: Velo — up 18%, with U.S. nicotine products also pulling their weight. Management liked what it saw enough to nudge full-year adjusted EPS guidance toward the middle of its 5–8% range.

That's the pitch: the great cigarette-to-nicotine-pouch migration is actually working, not just getting talked about on earnings calls.

Now the part the press release buried

Here's where the cynic in me perks up. While the adjusted metrics were popping champagne, the reported numbers were nursing a hangover. Reported profit from operations fell 15.8% to £4,266 million. Reported diluted EPS dropped 28.6% to 145.3p. That's not a rounding error — that's nearly a third of earnings evaporating once you stop letting the company decide what counts. The gap comes down to adjusting items, a tougher year-ago comparison, and softer contributions from associates, but it's a reminder that "adjusted" is a story management tells about the business, and "reported" is closer to what actually happened.

Layer on top of that persistent APMEA weakness and combustibles/heated products still shrinking, and you get a company that's genuinely transitioning — just not as cleanly as the highlight reel suggests. Even BAT's own guidance admits 2026 is likely to land at the lower end of its ranges, second-half weighted, which is management-speak for "trust us, it gets better later."

The valuation problem nobody wants to say out loud

Tobacco stocks are supposed to be cheap. That's the whole deal — you accept a dying core business in exchange for a bargain multiple and a fat dividend. BTI's trailing P/E has been running around 30x, which is not a "melting ice cube" multiple, it's closer to a consumer-staples-growth multiple. You're paying up for a transition story that, per the reported numbers, is still messier than the adjusted slides let on.

What actually keeps this stock interesting

To be fair to the bulls: a 5.65% dividend yield, ~$3.5B in free cash flow, and management reaffirming its mid-term "algorithm" (3–5% revenue, 4–6% profit, 5–8% EPS growth) is a real floor under this name. The stock's been consolidating around $59, boxed in by a 52-week range of roughly $49.88 to $67.30, RSI sitting neutral in the low 40s — no one's panicking, no one's chasing. This is a stock in a holding pattern waiting for a second-half acceleration to either show up or not.

The verdict

BTI is a hold, not a hero. The New Category growth is real and the guidance raise wasn't nothing, but the reported-vs-adjusted gap is a flashing yellow light, the APMEA soft patch hasn't resolved, and a 30x multiple leaves precious little room for disappointment in a business that still makes most of its money selling something governments are actively trying to make people quit. Collect the dividend, watch the debt load ($35B and counting), and don't confuse a well-dressed adjusted EPS number for the whole truth. The next real test isn't until BAT's full-year report, expected around February 2027 — until then, this is a stock for income investors with a strong stomach, not momentum chasers with a short one.